RSCM
CBIO

Rock Springs Capital Management’s Crescent Biopharma CBIO Stock Holding History

Rock Springs Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,250
Closed -$2.51M – 150
2017
Q2 		$2.51M Buy
+2,250
New +$1.86M 0.13% 123

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rock Springs Capital Management's CBIO Position: Q3 2017 in Review

Rock Springs Capital Management sold out of Crescent Biopharma (CBIO) in Q3 2017, closing a stake of 2,250 shares — an estimated $2.51M sold.

Rock Springs Capital Management first reported a position in CBIO in Q2 2017 and held it in 1 quarter. The position peaked at $2.51M in Q2 2017. 58 funds tracked by Wall St. Rank hold CBIO as of Q3 2017.

  • Rock Springs Capital Management reported no remaining Crescent Biopharma position as of Q3 2017 after selling out during the quarter.
  • Rock Springs Capital Management sold 2,250 Crescent Biopharma shares in Q3 2017, an estimated $2.51M.
  • Rock Springs Capital Management first reported a position in Crescent Biopharma in Q2 2017 and held it in 1 quarter.
  • Rock Springs Capital Management's Crescent Biopharma position peaked at $2.51M in Q2 2017.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2017.

Based on Rock Springs Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.